
Top insights from the Endpoints at ASCO McKesson leadership panel
Guided by our values, we are an impact-driven organization that improves care in every setting – one product, one partner, one patient at a time.
Through our core commitments, we are leveraging our scale for the greater good, such as serving the needs of our stakeholders, donating back to our communities, protecting our planet, working with policymakers, and more.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportOur businesses bring together leading technologies, innovative solutions and hands-on expertise to support the entire healthcare ecosystem.
We distribute pharmaceuticals and medical supplies to healthcare settings across North America, from pharmacies and hospitals to doctors’ offices and clinics.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
We provide research, insights, technologies and other support to help address challenges in cancer and specialty care.
We provide a suite of solutions designed to address access, affordability and adherence challenges by bridging the gaps between biopharma companies, pharmacies, providers, and payers to help patients get on and stay on their medications.
We offer solutions that enable employers, payers, health-plan brokers and government agencies to provide lower-cost options for prescription medications and therapies.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportLearn how McKesson is preparing its customers for implementation.
The Drug Supply Chain Security Act (DSCSA), signed into law on Nov. 27, 2013, outlines steps to achieve interoperable, electronic tracing of products at the package level to identify and trace certain prescription drugs as they are distributed in the United States. These requirements will enhance the FDA’s ability to help protect consumers from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful.
At McKesson, we’ve closely followed the DSCSA regulation and have continued to stay heavily engaged with the FDA, the manufacturing community and our competitors to help ensure that we are compliant and that our implementation plans are executed seamlessly across all aspects of the pharmaceutical supply chain.
Click here to learn how our company is helping customers prepare for these changes brought about by the DSCSA.
Top insights from the Endpoints at ASCO McKesson leadership panel
Insights and Takeaways for The Next Chapter in Specialty Medicine from Asembia AXS25
Insights from the 2025 CoverMyMeds Medication Access Report, From Barriers to Bridges
During the recent STAT @ ASH event in San Diego, panelists explored the role of community oncology in advancing precision medicine for cancer care.
Learn about McKesson’s new Cell and Gene Therapy (CGT) brand, InspiroGene, and the launch of a first-of-its-kind report about the CGT landscape and its future trajectory.
Milken Institute Future of Health Summit panelists address critical industry challenges and explore ways to futureproof the pharmaceutical supply chain.
The powerful tool assists McKesson Medical-Surgical customers with optimizing operations and cost savings, and helps ensure a more resilient supply chain.
Learn how we’re utilizing our strengths to help build a healthier, more equitable future.
Reforming healthcare data analytics with advanced technologies and automation, ensuring high-fidelity, analytics-ready data for life sciences.
McKesson's consolidation of brands sees Foster & Thrive offering a diverse range of products, catering to varied healthcare needs.